• About
    ▼
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    ▼
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Publications
  • Pipeline
    ▼
    • Overview
    • Ulviprubart
    • IBM
    • T-LGLL
    • T and NK Cell Lymphomas
    • Additional Indications
  • Clinical Trials
  • News
  • Careers
  • Contact
News

News

Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

  • About
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Publications
  • Pipeline
    • Overview
    • Ulviprubart
    • IBM
    • T-LGLL
    • T and NK Cell Lymphomas
    • Additional Indications
  • Clinical Trials
  • News
  • Careers
  • Contact

News

Abcuro Appoints Courtney Cupples as Chief Commercial Officer

June 9, 2025

Ms. Cupples brings extensive global commercial leadership and rare disease product launch experience Newton, Massachusetts, June 9, 2025 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Courtney Cupples as Chief Commercial Officer (CCO). Ms.

 READ MORE

READ MORE
June 9, 2025
Abcuro Appoints Courtney Cupples as Chief Commercial OfficerPress Releases

Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual Meeting

March 11, 2025

Newton, Massachusetts, March 11, 2025 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that the Company will present safety, pharmacokinetic, and pharmacodynamic data from the Phase 1 clinical trial evaluating ulviprubart (ABC008) for the treatment of inclusion

 READ MORE

READ MORE
March 11, 2025
Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual MeetingPress Releases

Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis

February 12, 2025

Series C financing led by NEA, joined by new investor Foresite Capital and Abcuro’s existing investors   Proceeds to support completion of the registrational Phase 2/3 MUSCLE trial of ulviprubart in inclusion body myositis, BLA filing, and commercial launch preparation Newton, Massachusetts, February 12, 2025 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for

 READ MORE

READ MORE
February 12, 2025
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body MyositisPress Releases

Abcuro Announces Participation in Upcoming Investor Conferences

November 11, 2024

Newton, Massachusetts, November 11, 2024 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Stifel 2024 Healthcare Conference: Presentation on November 18, 2024, at 3:00 pm

 READ MORE

READ MORE
November 11, 2024
Abcuro Announces Participation in Upcoming Investor ConferencesPress Releases

Abcuro Announces Participation in Upcoming Investor Conferences

August 29, 2024

Newton, Massachusetts, August 29, 2024 – Abcuro, Inc., a clinical stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Morgan Stanley 22nd Annual Global Healthcare Conference: Presentation on September 5, 2024,

 READ MORE

READ MORE
August 29, 2024
Abcuro Announces Participation in Upcoming Investor ConferencesPress Releases

Abcuro Appoints Sarah Boyce to its Board of Directors

July 31, 2024

Newton, Massachusetts, July 31, 2024 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Sarah Boyce to its Board of Directors. Ms. Boyce brings more than 25 years of global commercial leadership experience in the life

 READ MORE

READ MORE
July 31, 2024
Abcuro Appoints Sarah Boyce to its Board of DirectorsPress Releases

Abcuro Completes Enrollment of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart for the Treatment of Inclusion Body Myositis

June 25, 2024

Newton, Massachusetts, June 25, 2024 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the completion of enrollment of the registrational Phase 2/3 MUSCLE clinical trial evaluating ulviprubart (ABC008) for the treatment of inclusion body myositis (IBM). “We continue

 READ MORE

READ MORE
June 25, 2024
Abcuro Completes Enrollment of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart for the Treatment of Inclusion Body MyositisPress Releases

Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors

December 6, 2023

Newton, Massachusetts, December 6, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Mark Pruzanski, M.D., as Chairman of its Board of Directors. Dr. Pruzanski brings more than 30 years of experience as

 READ MORE

READ MORE
December 6, 2023
Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of DirectorsPress Releases

Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis

November 13, 2023

Newton, Massachusetts, November 13, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced initiation of Part B of the registrational Phase 2/3 MUSCLE clinical study, an ongoing clinical trial of ulviprubart (ABC008) for the treatment

 READ MORE

READ MORE
November 13, 2023
Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body MyositisPress Releases

Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline

August 17, 2023

Financing co-led by Redmile Group and Bain Capital Life Sciences Proceeds to support completion of Phase 2/3 registrational trial of ABC008, a first-in-class anti-KLRG1 antibody for the treatment of inclusion body myositis as well as continued development of additional clinical programs Newton, Massachusetts, August 17, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies

 READ MORE

READ MORE
August 17, 2023
Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune PipelinePress Releases

Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis

May 31, 2023

Company expects to have a Data Safety and Monitoring Board (DSMB) review by the end of this year  Newton, Massachusetts, May 31, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced completion of enrollment of the

 READ MORE

READ MORE
May 31, 2023
Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body MyositisPress Releases

Abcuro Initiates Registrational Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis

April 3, 2023

ABC008 potently and selectively depletes highly cytotoxic T cells which attack and destroy muscle tissue in IBM without affecting protective T cell populations  Newton, Massachusetts, April 3, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today

 READ MORE

READ MORE
April 3, 2023
Abcuro Initiates Registrational Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body MyositisPress Releases

Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia

October 4, 2022

T-LGLL is an autoimmune disorder characterized by cytotoxic T lymphocytes which attack neutrophils and red blood cell precursors Newton, Massachusetts, October 4, 2022 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced initiation of a Phase

 READ MORE

READ MORE
October 4, 2022
Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic LeukemiaPress Releases

Abcuro Appoints Alex Martin as Chief Executive Officer

October 3, 2022

 Industry veteran brings extensive experience in building and leading biopharmaceutical companies Newton, Massachusetts, October 3, 2022 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Alex Martin as Chief Executive Officer. He brings to

 READ MORE

READ MORE
October 3, 2022
Abcuro Appoints Alex Martin as Chief Executive OfficerPress Releases

Dietmar Berger, M.D., Ph.D., Joins Abcuro Therapeutics as Board Observer

June 23, 2022

Newton, Massachusetts, June 23, 2022– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that Dietmar Berger, M.D., Ph.D., currently the Chief Medical Officer and Head of Global Development at Sanofi will contribute his considerable experience to the company’s Board of

 READ MORE

READ MORE
June 23, 2022
Dietmar Berger, M.D., Ph.D., Joins Abcuro Therapeutics as Board ObserverPress Releases

Abcuro Appoints H. Jeffrey Wilkins, M.D., as Chief Medical Officer

June 21, 2022

Industry veteran brings extensive clinical development experience in immunology, immuno-oncology, and rare diseases to  leadership team Newton, Massachusetts, June 21, 2022– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of H. Jeffrey Wilkins, M.D.,

 READ MORE

READ MORE
June 21, 2022
Abcuro Appoints H. Jeffrey Wilkins, M.D., as Chief Medical OfficerPress Releases

Abcuro Presents Additional Data from Ongoing Phase 1 Clinical Trial of ABC008 in Inclusion Body Myositis (IBM) at GCOM 2022

June 7, 2022

Newton, Massachusetts, June 7, 2022, Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the presentation of additional clinical results from its ongoing Phase 1 clinical trial of its lead product candidate ABC008 in patients with inclusion

 READ MORE

READ MORE
June 7, 2022
Abcuro Presents Additional Data from Ongoing Phase 1 Clinical Trial of ABC008 in Inclusion Body Myositis (IBM) at GCOM 2022Press Releases

Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells

November 5, 2021

ABC008 is a first-in-class monoclonal antibody designed to selectively deplete highly cytotoxic T cells ABC008 offers therapeutic potential across a broad range of diseases in addition to inclusion body myositis, such as T cell large granular lymphocytic leukemia (T-LGLL) and mature T cell malignancies Newton, Massachusetts, November 5, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing

 READ MORE

READ MORE
November 5, 2021
Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T CellsPress Releases

Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors

October 19, 2021

Newton, Massachusetts, October 19, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Darlene Deptula-Hicks as a member of the company’s Board of Directors. Ms. Deptula-Hicks is a highly regarded financial executive with decades of experience

 READ MORE

READ MORE
October 19, 2021
Abcuro Appoints Darlene Deptula-Hicks to its Board of DirectorsPress Releases

Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress

October 6, 2021

Newton, MA, October 6, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that a Trial in Progress poster describing a Phase 1 trial of ABC008 will be presented at the Lymphoma, Leukemia and Myeloma Congress Conference being held

 READ MORE

READ MORE
October 6, 2021
Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma CongressPress Releases
  • 1
  • 2
  • Next Page »

Privacy Site Credits Terms of Use

© 2025 Abcuro